News Roche breast cancer drug Itovebi turned down by NICE NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.
News NICE backs Sobi's Tryngolza for rare disease FCS Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.
News MPs seek probe into UK-US pharma deal's impact on NHS The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
News NICE finally backs Enhertu for HER2-low breast cancer Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
News Wales takes UK lead on needle-free anaphylaxis prevention Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.
News NICE says no to Gilead's lenacapavir for HIV PrEP NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.